Recent trends in anti-vascular endothelial growth factor intravitreal injections: a large claims database study in Japan

15Citations
Citations of this article
11Readers
Mendeley users who have this article in their library.

Abstract

Purpose: To clarify recent trends in the use of intravitreal injections of anti-vascular endothelial growth factor (VEGF) in Japan. Study design: Retrospective cohort study. Methods: We used the DeSC database, a large-scale claims database for Japan, for entries between April 2014 and March 2021. We counted the number of anti-VEGF drug injections (aflibercept, ranibizumab, brolucizumab, and pegaptanib) administered every year, calculated the sex- and age-adjusted injection rates, and stratified these rates according to sex, age categories, anti-VEGF drugs, and diagnoses. We also calculated the number of injections administered within one year after the first injection according to the diagnoses. Results: In total, 164,451 cases of anti-VEGF injections were identified. The sex- and age-adjusted rates of anti-VEGF injections per 1000 person-years increased from 7.9 in 2014 to 16.1 in 2020. Men were approximately twice as likely to receive anti-VEGF injections than women. The 70–79, 80–89, and ≥90 age categories had the highest rates, accounting for approximately 80%. Neovascular age-related macular degeneration had the highest rate, accounting for 60–70% over the study period. Aflibercept was the most commonly used drug, accounting for approximately 80% over the study period. The average number of injections within one year after the first injection was 4.4 for neovascular age-related macular degeneration, 2.7 for branch retinal vein occlusion, 3.1 for central retinal vein occlusion, and 3.5 for diabetic macular edema in 2020. Conclusion: These findings can be used as a benchmark for the clinical practice of anti-VEGF therapy.

Cite

CITATION STYLE

APA

Hashimoto, Y., Okada, A., Matsui, H., Yasunaga, H., Aihara, M., & Obata, R. (2023). Recent trends in anti-vascular endothelial growth factor intravitreal injections: a large claims database study in Japan. Japanese Journal of Ophthalmology, 67(1), 109–118. https://doi.org/10.1007/s10384-022-00969-2

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free